Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Int J Nanomedicine. 2021 Jan 12;16:315-327. doi: 10.2147/IJN.S281710. eCollection 2021.
Castration-resistant prostate cancer (CRPC) is still considered incurable, even though the mechanisms of CRPC had been extensively researched. Studies have demonstrated that exosomes in the tumor microenvironment contribute to prostate cancer development and progression. However, the role of exosomes in the process of CRPC progression has not yet been determined.
Co-culturing and exosome treatment assays combined with in vitro and in vivo assays were performed to determine the function of exosomes in the transformation of androgen-dependent prostate cancer (ADPC) cells into androgen-independent cells. Then, the mRNA expression profiles of ADPC cells and ADPC cells co-cultured with androgen-independent prostate cancer (AIPC) cell-derived exosomes were studied using microarrays. After silencing the expression of heme oxygenase-1 (HMOX1), Western blotting, quantitative real-time PCR, immunohistochemistry (IHC) studies, and MTS assay were used to confirm the mechanisms of exosome participation in CRPC progression.
The results showed that ADPC cells acquired tolerance for androgen deprivation due to the exosome-mediated communication between cells. AIPC cell-derived exosomes promoted the transformation of ADPC cells into androgen-independent cells in vivo and in vitro. Microarray analysis revealed that HMOX1 in ADPC cells was up-regulated after treatment with AIPC cell-derived exosomes. Further results showed that HMOX1 is overexpressed in human AIPC specimens and protects ADPC cells from androgen deprivation.
Our findings revealed that exosomes contribute to CRPC progression via promoting the transition of prostate cancer cells into an androgen-independent growth stage by activating HMOX1.
去势抵抗性前列腺癌(CRPC)仍被认为是无法治愈的,尽管已经对 CRPC 的机制进行了广泛研究。研究表明,肿瘤微环境中的外泌体有助于前列腺癌的发展和进展。然而,外泌体在 CRPC 进展过程中的作用尚未确定。
通过共培养和外体处理实验,结合体外和体内实验,确定外泌体在雄激素依赖性前列腺癌(ADPC)细胞向雄激素非依赖性细胞转化过程中的作用。然后,使用微阵列研究 ADPC 细胞和与雄激素非依赖性前列腺癌细胞(AIPC)细胞来源的外泌体共培养的 ADPC 细胞的 mRNA 表达谱。沉默血红素加氧酶-1(HMOX1)的表达后,使用 Western blot、定量实时 PCR、免疫组织化学(IHC)研究和 MTS 测定法来确认外泌体参与 CRPC 进展的机制。
结果表明,由于细胞间的外体介导的通讯,ADPC 细胞获得了对雄激素剥夺的耐受性。AIPC 细胞来源的外泌体在体内和体外促进 ADPC 细胞向雄激素非依赖性细胞的转化。微阵列分析显示,ADPC 细胞在用 AIPC 细胞来源的外泌体处理后 HMOX1 上调。进一步的结果表明,HMOX1 在人 AIPC 标本中过表达,并保护 ADPC 细胞免受雄激素剥夺。
我们的研究结果表明,外泌体通过激活 HMOX1 促进前列腺癌细胞向雄激素非依赖性生长阶段的转变,从而促进 CRPC 的进展。